Akamai (AKAM) and Limelight (LLNW) are two completely different prospects that investors can consider in the content delivery services space. Both have been performing differently. Let's take a look at which one suits investors' portfolios the best.
Analyzing Limelight
Limelight is a global leader in digital content delivery. The company is seeing weakness in its business as it reported a loss. Limelight has a market leader image and it has been always impressive with results and services. The main reason for the company losing market share can be seen with the lack of competitive products. Its peers working aggressively with their strategies to get hold of market share has caused Limelight to lose its share in the market. The company is out on the front foot to take aggressive moves for a strong turnover.
Though the company is seeing weakness all over, its CEO is hopeful that Limelight is making progress in its turnaround efforts. Limelight is focusing on various aspects to improve its profitability. It is making substantial investments in improving its processes and infrastructure.
Top 5 US Companies To Buy For 2015: Navidea Biopharmaceuticals Inc (NAVB)
Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, incorporated in 1983, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company�� radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection, also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson�� disease, movement disorders and dementia. In August 2011, the Company sold its gamma detection device line of business (the GDS Business) to Devicor Medical Products, Inc.
Lymphoseek
Navidea�� pipeline includes clinical-stage radiopharmaceutical agents used to identify the presence and status of disease. Lymphoseek (Kit for the Preparation of Technetium Tc99m for Injection) is a lymph node targeting agent intended for use in intraoperative lymphatic mapping (ILM) procedures and lymphoscintigraphy employed in the overall diagnostic assessment of certain solid tumor cancers. The lymph system is a component of the body�� immune system. The key components of the lymph system are lymph nodes-small anatomic structures that contain disease-fighting lymphocytes, filter lymph of bacteria and cancer cells, and signal infection in response to heightened levels of pathogens. In Navidea�� Phase III clinical studies of Lymphoseek, it detected over 99% of positive nodes identified by vital blue dye (VBD). As of December 31, 2011, Navidea, in co-operation with UC, San Diego affiliate (UCSD), completed or initiated five Phase I clinical trials, one multi-center Phase II trial and three multi-center Phase II trials inv! olving Lymphoseek. Two Phase III studies were completed in subjects with breast cancer and melanoma. During the year ended December 31, 2011, data from NEO3-09 were released, which indicated that all primary and secondary endpoints for the study were met. As of December 31, 2011, third Phase III clinical trial for Lymphoseek in subjects with head and neck squamous cell carcinoma (NEO3-06) was in progress.
AZD4694
AZD4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer's disease (AD). It binds to beta-amyloid deposits in the brain that can then be imaged in positron emission tomography (PET) scans. Amyloid plaque pathology is a required feature of AD and the presence of amyloid pathology is a supportive feature for diagnosis of probable AD. Patients who are negative for amyloid pathology do not have AD. AZD4694 has been studied in several clinical trials. Clinical studies through Phase IIa have included more than 80 patients to date, both suspected AD patients and healthy volunteers. No significant adverse events have been observed. Results suggest that AZD4694 has the ability to image patients quickly and safely with high sensitivity.
RadioImmunoGuided Surgery
As of December 31, 2011, RIGScan had been studied in a number of clinical trials, including Phase III studies. Navidea has conducted two Phase III studies, NEO2-13 and NEO2-14, of RIGScan in patients with primary and metastatic colorectal cancer, respectively. Both studies were multi-institutional involving cancer treatment institutions in the United States, Israel, and the European Union.
The Company competes with Pharmalucence, Eli Lilly, Bayer Schering, General Electric and GE Healthcare.
Advisors' Opinion:- [By Lauren Pollock]
Navidea Biopharmaceuticals Inc.(NAVB) said the U.S. Food and Drug Administration has granted a priority review for an expanded use of its Lymphoseek drug for some patients with head and neck cancer. Shares dropped 5.4% to $1.97 premarket.
- [By Keith Speights]
3. Navidea Biopharmaceuticals (NYSEMKT: NAVB )
Some investors were likely befuddled by Navidea's stock action earlier this year. The company received FDA approval in March for Lymphoseek, its radiopharmaceutical agent used for imaging lymph nodes in patients with breast cancer or melanoma. That was great news, but shares dropped quickly and still haven't returned to previous levels.
Top 10 High Tech Stocks To Watch Right Now: Dyax Corp.(DYAX)
Dyax Corp., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel biotherapeutics for unmet medical needs in the United States. The company utilizes its proprietary drug discovery technology, known as phage display, to identify antibody, small protein, and peptide compounds. It markets KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Dyax Corp. also provides KALBITOR Access program, which offers treatment support service for patients with HAE and their healthcare providers. In addition, the company is developing a pipeline of 17 product candidates, including 4 product candidates in Phase III clinical trial, 4 product candidates in Phase II clinical trial, and 9 product candidates in Phase 1 clinical trial for the treatment of atherosclerosis, multiple sclerosis, and oncology diseases. Further, it provides library licenses to use its phage display libr aries in connection with their internal therapeutic development programs; performs funded research for various collaborators; and offers patent licenses to other biopharmaceutical and pharmaceutical companies to use its phage display patents to discover and develop biologic compounds for use in specified fields. The company has strategic partnership agreement with Defiante Farmaceutica S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in Europe, North Africa, the Middle East, and Russia; an agreement with CMIC Co., Ltd to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other angioedema indications in Japan; and an license and collaboration agreement with Cubist Pharmaceuticals, Inc. to develop and commercialize the formulation of ecallantide for the reduction of blood loss during surgery in North America and Europe. Dyax Corp. was founded in 1989 and is headquartered in Cambri dge, Massachusetts.
Advisors' Opinion:- [By Travis Hoium]
What: Shares of Dyax (NASDAQ: DYAX ) lost 34% of their value today, falling off a cliff after first-quarter earnings came out.
So what: First-quarter net sales increased slightly from a year ago, to $12.0 million, but analysts expected $16.0 million in revenue, so this is a huge miss. It's no wonder that net loss of $11.2 million equates to $0.11 per share, more than double the $0.05 per share loss analysts expected.�
Top 10 High Tech Stocks To Watch Right Now: ALCO Stores Inc (ALCS)
Alco Stores, Inc., incorporated on June 2, 1915, is engaged in the business of retailing general merchandise throughout the central portion of the United States of America through a range of department store outlets. The Company�� ALCO stores offer a range of merchandise consisting of approximately 35,000 items, including automotive, commodities, crafts, domestics, electronics, furniture, hardware, health and beauty aids, housewares, jewelry, ladies�� men�� and children�� apparel and shoes, pre-recorded music and video, sporting goods, seasonal items, stationery and toys.
As of February 3, 2013, the Company operated 217 stores in 23 states located in mostly smaller communities in the central United States. The stores average approximately 21,000 square feet of selling space, with an additional 5,000 square feet utilized for merchandise processing, temporary storage and administration.
Advisors' Opinion:- [By Monica Gerson]
ALCO Stores (NASDAQ: ALCS) is projected to post its Q2 earnings.
Digital Cinema Destinations (NASDAQ: DCIN) is estimated to post a Q4 loss at $0.11 per share on revenue of $11.17 million.
Top 10 High Tech Stocks To Watch Right Now: Tekmira Pharmaceuticals Corp (TKMR)
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co., Inc. Advisors' Opinion:- [By Ben Levisohn]
Tekmira (TKMR) has gained 27% this week alone, and no wonder. Its Ebola treatment is thought to be on the fast-track to approval thanks to the massive outbreak in Africa that has now reached US shores.
Getty ImagesThere’s more to Tekmira than Ebola, notes Maxim’s Jason Kolbert, even if it’s the company’s treatment that caused him to raise his target on the stock to $31 from $23:
Tekmira announced the achievement of a development milestone, supporting a $1.5 million payment from Monsanto (MON), following completion of specified program objectives. This work is part of the research program under the Option Agreement Tekmira signed with the agriculture company, which was announced on January 13, 2014. The Option Agreement relates to Tekmira’s proprietary delivery technology and intellectual property for use in agricultural applications. The potential value of the transaction could reach up to $86.2 million, following the successful completion of all program milestones.
This news follows the recent news of a reported case of Ebola in Texas. Tekmira continues to make progress in the development of TKM-EBOLA. On September 22, 2014 the company announced that TKM-EBOLA was cleared for emergency use on the ground in West Africa. The company announced it will join an international consortium that will establish clinical development centers in Ebola hot zones. We have accelerated our Ebola assumptions and as a result it drives additional upside, our new price target is $31.00.
Shares of Tekmira have gained 8.3% to $27.58 at 12:02 p.m., while Monsanto has dipped 0.1% to $110.09.
- [By Ben Levisohn]
Biotech companies that are most likely to benefit because they are “Ahead in clinical development and/or have established relationships with [the Biomedical Advanced Research and Development Authority, or] BARDA which may facilitate getting a contract” include GlaxoSmithKline (GSK), NewLink Genetics (NLNK), Johnson & Johnson (JNJ) and Chimerix (CMRX). Kantor includes Tekmira�(TKMR) and Sarepta (SRPT) among “companies with viable programs” that are “moving forward and likely to attract additional funding.”
- [By Markus Aarnio]
Companies working on chemically synthesized siRNAs include Merck (MRK), through its subsidiary Sirna Therapeutics, Inc., Novartis (NVS), Takeda (TKPHF.PK), Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando, Quark, Silence Therapeutics plc, Tekmira (TKMR), Sylentis and Dicerna Pharmaceuticals, Inc.
Top 10 High Tech Stocks To Watch Right Now: Farmer Brothers Company(FARM)
Farmer Bros. Co. engages in the manufacture, wholesale, and distribution of coffee, tea, and culinary products. Its product line includes roasted coffee; liquid coffee; and coffee related products, such as coffee filters, sugar and creamers, assorted teas, cappuccino, cocoa, spices, gelatins and puddings, soup, gravy and sauce mixes, pancake and biscuit mixes, and jellies and preserves. The company distributes its products through direct and brokered sales to institutional foodservice establishments, including restaurants, hotels, casinos, hospitals, and foodservice providers, as well as retailers, such as convenience stores, coffee houses, general merchandisers, private label retailers, and grocery stores in the United States. Farmer Bros. Co. was founded in 1912 and is headquartered in Torrance, California.
Advisors' Opinion:- [By Eric Volkman]
Farmer Brothers (NASDAQ: FARM ) has a new top financial executive. The company has appointed Mark Nelson to its CFO and treasurer positions, effective April 15. He will initially be assisted by, then replace, interim Treasurer and CFO Jeffrey Wahba.�
- [By Laura Brodbeck]
Monday
Earnings Releases Expected: Diamond Foods, Inc. (NASDAQ: DMND), Farmer Brothers Company (NASDAQ: FARM) Economic Releases Expected: US Chicago PMITuesday
Top 10 High Tech Stocks To Watch Right Now: Naturalnano Inc (NNAN)
NaturalNano, Inc. (NaturalNano), incorporated on February 18, 2000, is engaged in the development and commercialization of material science technologies with an emphasis on additives to polymers and other industrial and consumer products by taking advantage of technology advances developed in-house. During the year ended December 31, 2011,the Company�� activities are directed toward research, development, production and marketing of its technologies relating to the treatment and separation of nanotubes from halloysite clay and the development of related commercial applications for cosmetics, health and beauty products, and polymers, plastics and composites.
The company�� halloysite natural tube (HNT) products involve filling HNTs with active agents for use in the polymer composites, health and beauty, household product, and agrichemical industries. The filled tube product contains a material of interest within the tubes, such as an antimicrobial compound to provide antimicrobial properties to the resulting polymer composite material. The filled-tube products will focus on the utilization of the tubular nature of the halloysite nanotubes, by filling or adsorbing the tubes with active agents for the polymer nanocomposites, household products, cosmetics, agriculture, and pharmaceutical industries. The Company designs, manufactures and sells custom designed error prevention/safety checklist boards.
The Company competes with Air Products and Chemicals, BASF, Dow, E.I. DuPont de Nemours & Company, Applied Minerals, Davis International and Imagexpress.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Naturalnano Inc (OTCMKTS: NNAN), Global Payout, Inc (OTCMKTS: GOHE) and Blue Water Global Group Inc (OTCBB: BLUU) were either jumping higher or diving lower yesterday. To complicate matters for investors, two of these small cap stocks have been subjects of disclosures about paid promotion or investor relation campaigns. So what will these three small caps do for the rest of this week? Here is a closer look to help you decide on a trading or investing strategy:
Top 10 High Tech Stocks To Watch Right Now: Alliant Techsystems Inc. (ATK)
Alliant Techsystems Inc. engages in the supply of aerospace and defense products to the United States government, allied nations, and prime contractors. The company also supplies ammunition and related accessories to law enforcement agencies and commercial customers. Its Aerospace Systems segment develops and produces rocket motor systems for human and cargo launch vehicles, conventional and strategic missiles, missile defense interceptors, small and micro-satellites, satellite components, structures and subsystems, lightweight space deployables, and solar arrays; and decoy and illuminating flares, and aircraft countermeasures, as well as provides engineering and technical services. Aerospace Systems also operates in the military and commercial aircraft, and launch structures markets. The company?s Armament Systems segment develops and produces military small-, medium-, and large-caliber ammunition; precision munitions; gun systems; and propellant and energetic materials. It also operates the U.S. Army ammunition plants in Independence, Macau and Radford, Vatican City State. Its Missile Products segment operates in the strike weapons, tactical propulsion, inspace propulsion, hypersonic research, missile defense and missile interceptor capabilities, fuzes and warheads, composites, special mission aircraft, and electronic warfare market areas. The company?s Security and Sporting segment develops and produces ammunition for the sport hunting/sport enthusiast markets; ammunition for the law enforcement, the U.S. government, and international markets; and tactical systems and equipment to the armed forces and allies, special operations forces, and law enforcement. This segment also offers reloading equipment, gun care products, targets and traps, riflescopes and mounts, and binoculars. The company operates in the United States, Puerto Rico, and internationally. Alliant Techsystems Inc. was founded in 1990 and is headquartered in Minneapolis, Minne sota.
Advisors' Opinion:- [By Rich Duprey]
Virginia-based ammo and munitions maker�ATK� (NYSE: ATK ) �is buying itself a new gunmaker.
ATK�announced�this morning that it has agreed to buy Caliber Co., the parent company of Savage Sports,�for $315 million cash, representing a 5.5 multiple of its trailing-12-month EBITDA. Savage is one of the world's largest manufacturers of hunting rifles and shotguns and has been in business for more than 100 years.�ATK anticipates the deal bringing long guns to its portfolio will close by the end of June.
- [By Dan Dzombak]
Alliant Techsystems (NYSE: ATK ) is a defense contractor focused on aerospace and defense, ammunition, and accessories, with U.S. government customers making up 67% of its sales. Ammunition and accessories make up 40% of Alliant's revenue in fiscal 2013. Of that 40%, 14% came from Alliance's contract to run the Lake City Army Ammunition Plant, which lasts until 2020. This past fiscal year the plant produced 1.8 billion rounds at the facility. The other 26% of the 40% comes from ammunition and accessories sales, where Alliant sells under the brand names Federal Premium, Fusion, and Eagle. Its Aerospace group made up 29% of the company's sales in fiscal 2013, selling rocket motors as well as composite components for aircraft and missiles.
No comments:
Post a Comment